In vivo CAR-T race for autoimmune grows as two RNA startups enter the clinic
THE SO WHAT
In vivo CAR-T for autoimmune moving into human trials shifts cell therapy from bespoke, ex vivo workflows to something that looks more like a repeatable drug platform. If you’re in healthcare delivery or biotech tooling, assume the bottleneck moves from lab capacity to in-clinic monitoring, data, and safety infrastructure over the next cycle.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging Tech'If these centers aren’t thoughtfully planned and coordinated, they can place extraordinary demands on electric infrastructure, the surrounding environment and host communities': Maine becomes first US state to pass data centre construction ban
A statewide moratorium on >20 MW data centers until November 1, 2027 turns power from a procurement line item into a regulatory minefield. If your AI roadmap assumes frictionless data center expansion, you now need a state-by-state permitting and grid-risk map sitting next to your model roadmap.
Deep & Emerging TechAI Could Democratize One of Tech's Most Valuable Resources
If AI makes chip design and software–silicon co-optimization cheaper, the constraint shifts from EDA talent to access to fabs and packaging. Foundry relationships and supply-chain leverage — not just model quality — will decide who actually benefits from this ‘democratization.’
Deep & Emerging TechThe musician-turned-biotech-founder waiting to fundraise
Biotech is reminding operators that money without a commercialization and regulatory path is just expensive hope. If you’re building in regulated tech — AI in health, finance, infra — treat your go-to-market and compliance architecture as part of the science, not an afterthought to bolt on once a celebrity check clears.
The US Air Force just offered a fresh look at its new B-21 stealth bomber
A major defense program staying on schedule and budget is a reminder that when the mission is existential, governments will absorb complexity and cost to modernize. Dual-use builders should read this as a timing cue — defense is ready to operationalize advanced systems while commercial buyers are still debating pilots.